ClinicalTrials.gg

Program

Daxokafusp Alfa

In Sanofi's pipeline, PD1xIL15 fusion protein. Its studies are mostly in Stomach Neoplasms, led by Sanofi.

Furthest: phase 2, since Oct 7, 20222 company-led studies, 2 open or runningNext primary completion: Jan 19, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi22 open or runningphase 2since Oct 7, 2022Oct 7, 2022Jan 19, 2027phase 2 · NCT05584670
  • Named in Sanofi’s own pipeline as SAR445877, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 7, 2022First study: phase 2 study in Solid TumorFirst studyNCT05584670 · 542 planned · United States, Chile, Israel and more
  2. Jun 24, 2026Phase 2 study in Stomach NeoplasmsNCT07692204 · 30 planned · China

Ahead

  1. Jan 19, 2027Primary completion: phase 2 study in Solid TumorNCT05584670
  2. Aug 2, 2028Primary completion: phase 2 study in Stomach NeoplasmsNCT07692204

TargetBeta

“PD1xIL15 fusion protein”the company's pipeline, read by Claude · source
“A fusion protein composed of an antibody moiety targeting the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) fused to a mutein of the immunostimulatory cytokine interleukin-15 (IL-15), with potential immune checkpoint inhibitory, immunomodulatin…”NCIt, read by Claude
“A fusion protein composed of an antibody moiety targeting the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) ”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07692204Stomach Neoplasms · China2RecruitingAug 2, 202830
NCT05584670Solid Tumor · United States, Chile, Israel and more2RecruitingJan 19, 2027542

How it is read

Names in the registry

  • “SAR445877”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.